Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.

Wada M, Marusawa H, Yamada R, Nasu A, Osaki Y, Kudo M, Nabeshima M, Fukuda Y, Chiba T, Matsuda F.

J Viral Hepat. 2009 Jun;16(6):388-96. doi: 10.1111/j.1365-2893.2009.01095.x. Epub 2009 Feb 5.

PMID:
19200137
2.

Polymorphisms in the IFNAR1 gene in patients with chronic hepatitis C: outcome of combined IFN-alpha therapy.

Tena-Tomás C, Pedroso ML, de Messias-Reason IJ, Kremsner PG, Kun JF.

Eur Cytokine Netw. 2007 Sep;18(3):136-41. Epub 2007 Sep 7.

3.

Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.

Nachnani JS, Rao GA, Bulchandani D, Pandya PK, Alba LM.

Ann Hematol. 2010 Feb;89(2):121-5. doi: 10.1007/s00277-009-0774-y. Epub 2009 Jun 30.

PMID:
19565241
4.

CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan.

Konishi I, Horiike N, Hiasa Y, Michitaka K, Onji M.

Intervirology. 2004;47(2):114-20.

PMID:
15192276
5.

Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection.

Wietzke-Braun P, Maouzi AB, Mänhardt LB, Bickeböller H, Ramadori G, Mihm S.

Eur J Gastroenterol Hepatol. 2006 Sep;18(9):991-7.

PMID:
16894313
6.

A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C.

Tsukada H, Ochi H, Maekawa T, Abe H, Fujimoto Y, Tsuge M, Takahashi H, Kumada H, Kamatani N, Nakamura Y, Chayama K.

Gastroenterology. 2009 May;136(5):1796-805.e6. doi: 10.1053/j.gastro.2009.01.061. Epub 2009 Jan 31.

PMID:
19208361
7.

Liver expression of proteins controlling interferon-mediated signalling as predictive factors in the response to therapy in patients with hepatitis C virus infection.

Bautista D, Bermúdez-Silva FJ, Lasarte JJ, Rodriguez-Fonseca F, Baixeras E.

J Pathol. 2007 Nov;213(3):347-55.

PMID:
17940994
8.

IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C.

Sharvadze L, Gochitashvili N, Tophuria A, Bolokadze N, Tsertsvadze T.

Georgian Med News. 2007 Jun;(147):52-5.

PMID:
17660602
9.

The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load.

Arase Y, Suzuki F, Sezaki H, Kawamura Y, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Yatsuji H, Hirakawa M, Kobayashi M, Ikeda K, Kumada H.

Intervirology. 2008;51(4):265-9. doi: 10.1159/000160216. Epub 2008 Oct 7.

PMID:
18841028
10.

Single-nucleotide polymorphisms in GALNT8 are associated with the response to interferon therapy for chronic hepatitis C.

Nakano R, Maekawa T, Abe H, Hayashida Y, Ochi H, Tsunoda T, Kumada H, Kamatani N, Nakamura Y, Chayama K.

J Gen Virol. 2013 Jan;94(Pt 1):81-9. doi: 10.1099/vir.0.044396-0. Epub 2012 Oct 3.

PMID:
23034592
11.

Association of interferon regulatory factor-7 gene polymorphism with liver cirrhosis in chronic hepatitis C patients.

Sermasathanasawadi R, Kato N, Muroyama R, Dharel N, Shao RX, Chang JH, Li CZ, Kawabe T, Omata M.

Liver Int. 2008 Jul;28(6):798-806. doi: 10.1111/j.1478-3231.2008.01725.x.

PMID:
18397234
12.

Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience.

Tanioka D, Iwasaki Y, Araki Y, Osawa T, Ikeda H, Ando M, Kobashi H, Sakaguchi K, Shiratori Y, Yamamoto K.

Liver Int. 2009 May;29(5):721-9. doi: 10.1111/j.1478-3231.2008.01964.x. Epub 2009 Jan 6.

PMID:
19141025
13.

A non-synonymous single nucleotide polymorphism in IFNAR1 affects susceptibility to chronic hepatitis B virus infection.

Zhou J, Smith DK, Lu L, Poon VK, Ng F, Chen DQ, Huang JD, Yuen KY, Cao KY, Zheng BJ.

J Viral Hepat. 2009 Jan;16(1):45-52. doi: 10.1111/j.1365-2893.2008.01040.x. Epub 2008 Aug 28.

PMID:
18761606
14.

Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response.

Rao HY, Wei L, Li J, Zhang LF, Chen HY, Zhu LM, Liu F, Sun Y, Wang H.

Hepatogastroenterology. 2009 Mar-Apr;56(90):328-34.

PMID:
19579592
15.

Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings.

Yoshida K, Alagbe O, Wang X, Woolwine B, Thornbury M, Raison CL, Miller AH.

Neuropsychobiology. 2005;52(2):55-61. Epub 2005 Jun 29.

PMID:
15990456
16.
17.

[Side effects of interferon therapy for chronic hepatitis C].

Arase Y.

Nihon Rinsho. 2006 Jul;64(7):1363-7. Review. Japanese.

PMID:
16838657
18.

Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study.

King JK, Yeh SH, Lin MW, Liu CJ, Lai MY, Kao JH, Chen DS, Chen PJ.

Hepatology. 2002 Dec;36(6):1416-24.

PMID:
12447867
19.

Necessities of interferon therapy in elderly patients with chronic hepatitis C.

Ikeda K, Arase Y, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Kumada H.

Am J Med. 2009 May;122(5):479-86. doi: 10.1016/j.amjmed.2008.09.045.

PMID:
19375558
20.

Enhanced expression of suppressor of cytokine signalling-1 in the liver of chronic hepatitis C: possible involvement in resistance to interferon therapy.

Imanaka K, Tamura S, Fukui K, Ito N, Kiso S, Imai Y, Naka T, Kishimoto T, Kawata S, Shinomura Y; Kansai Viral Hepatitis Research Group.

J Viral Hepat. 2005 Mar;12(2):130-8.

PMID:
15720527

Supplemental Content

Support Center